BT8009

Phase 3

BICYCLE THERAPEUTICS PLC (BCYC)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jan '27

BCYCPhase 2$253M

BT8009 Phase 2 Est. Readout

BT8009• Urinary Bladder Neoplasm329

Jan 2027~Estimated

CT.gov

00%

Competitive Landscape

1 competitor in Urinary Bladder Neoplasm

NKTRBempegaldesleukin

Phase 2

View Full Landscape

Drug Information

Target Indication

Urinary Bladder Neoplasm

Clinical Trial

NCT04561362

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BCYC

BICYCLE THERAPEUTICS PLC

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

Gemcitabine + cisplatin Or carboplatinPhase 3

Metastatic Urothelial Cancer

BT5528Phase 2

Advanced Solid Tumor Historically Known for High EphA2 Expression

BT7480Phase 2

Advanced Solid Tumor

Zelenectide pevedotin (BT8009)Phase 2

Non-Small Cell Lung Cancer

nuzefatide pevedotin (BT5528)Phase 2

Pancreatic Ductal Adenocarcinoma (PDAC)

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts